Document ID: chunk:federal_register_of_legislation:C2007A00111:clause:1_99acc:p2
Version: federal_register_of_legislation:C2007A00111
Segment Type: clause
Provision Reference: sch 1 cl 99ACC (pt 2/2)
Character Range: 40252–41909

Minister:
 (c) may have regard to the advice referred to in subsection (4) in relation to the combination item; and
 (d) must take into account, in relation to the listed component drug, or each listed component drug, that became subject to statutory price reduction:
 (i) the approved price to pharmacists, on the reduction day, of each brand of a pharmaceutical item that has the drug that is the listed component drug; and
 (ii) the quantity of the listed component drug contained in the combination item.

 (4B) If subsection (4) does not apply, then, in agreeing the new price of the single brand of the combination item, the Minister must take into account, in relation to the listed component drug, or each listed component drug, that became subject to statutory price reduction:
 (a) the approved price to pharmacists, on the reduction day, of each brand of a pharmaceutical item that has the drug that is the listed component drug; and
 (b) the quantity of the listed component drug contained in the combination item.

Section does not limit Minister's powers

 (5) This section does not limit the Minister's powers, after the reduction day, to make further price agreements in relation to the single brand of the combination item.

Subject to statutory price reduction

 (6) A listed component drug contained in a drug in a combination item becomes subject to statutory price reduction if any of the following has applied to a listed brand of a pharmaceutical item that has a drug that is the listed component drug:
 (a) section 99ACB;
 (b) subsection 99ACF(1) or (2) because of any of the items in the table in that section;
 (c) section 99ADH.